News and Announcements
Hazer Group Ltd (ASX:HZR) Completes Commission of Pre-Pilot Plant
- Published July 06, 2017 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Hazer Group Ltd (ASX:HZR) is pleased to announce the success of commissioning of the Company’s pre-pilot plant, located in St Marys in Western Sydney. This marks a significant inflexion point in Hazer’s development trajectory, with the pre-pilot plant now ready to commence the operational experimentation phase.
KEY TAKEAWAYS:
- Commissioning of Pre-Pilot Plant now complete.
- Marks and important milestone in Hazers scale-up road map.
- Pre-Pilot Plant now ready to commence operational experimentation phase.
Furthermore, various process design and operational optimisation opportunities have already been identified during the commissioning phase, and will be progressed as part of ongoing operations of the pre-pilot plant.
Hazer Group Managing Director Geoff Pocock said: “This successful commissioning will now allow Hazer to continue its transition from laboratory-based development to functional industrial technology. The pre-pilot plant enables us to evaluate the performance of the Hazer Process at temperature, pressure and in a fluidised state and advance our development strategy to demonstrate our technology can operate at this scale and beyond.”
Once operational in fully continuous mode, the pre-pilot plant will be used to generate data necessary for the design and construction of Hazer’s next plant – a commercial prototype facility that is expected to be of a greater scale, ideally suited to the vehicle refuelling market.
Company Updates
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
The Light Fantastic: Why Invion’s Photodynamic Therapy May Be Attracting Big Pharma’s Attention
Invion Limited is challenging the status quo in oncology with its Photosoft™ platform, a precision therapy that uses light-activated molecules to selectively target cancer cells. By transforming the body’s own immune response and addressing the high costs of current cancer treatments, Invion is positioning itself as a transformative player in the biotech sector. With clinical trials underway and strong institutional partnerships, the company is bridging the gap between scientific breakthrough and accessible, scalable patient care.
From Outback to Boardroom: How SWAN Systems is Codifying Water Stewardship
From the arid deserts of Australia to the boardrooms of global tech giants, SWAN Systems is redefining water efficiency. By bridging the gap between field-level agronomics and autonomous irrigation control, the company is proving that “water-positive” targets can be met with science, data, and a 10x ROI commitment.
Backed By Leading Investment Groups and Family Offices
